Medical oncology Unit, Oncology Center Mansoura University, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Clinical Hematology Unit, Oncology Center Mansoura University, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Ann Hematol. 2023 Jun;102(6):1287-1300. doi: 10.1007/s00277-023-05241-2. Epub 2023 May 2.
Philadelphia chromosome-like (Ph-like) ALL is a recent subtype of acute lymphoblastic leukemia. Although it does not express the BCR-ABL fusion gene, it has a behavior like true BCR/ABL1-positive cases. This subtype harbors different molecular alterations most commonly CRLF2 rearrangements. Most cases of Ph-like ALL are associated with high white blood cell count, high minimal residual disease level after induction therapy, and high relapse rate. Efforts should be encouraged for early recognition of Ph-like ALL to enhance therapeutic strategies. Recently, many trials are investigating the possibility of adding the tyrosine kinase inhibitor (TKI) to chemotherapy to improve clinical outcomes. The role and best timing of allogeneic bone marrow transplant in those cases are still unclear. Precision medicine should be implemented in the treatment of such cases. Here in this review, we summarize the available data on Ph-like ALL.
费城染色体样(Ph-like)ALL 是急性淋巴细胞白血病的一种新亚型。尽管它不表达 BCR-ABL 融合基因,但它的行为类似于真正的 BCR/ABL1 阳性病例。这种亚型具有不同的分子改变,最常见的是 CRLF2 重排。大多数 Ph-like ALL 病例与高白细胞计数、诱导治疗后微小残留病灶水平高和复发率高有关。应鼓励早期识别 Ph-like ALL,以加强治疗策略。最近,许多试验正在研究将酪氨酸激酶抑制剂(TKI)添加到化疗中以改善临床结果的可能性。同种异体骨髓移植在这些病例中的作用和最佳时机仍不清楚。应该在这些病例的治疗中实施精准医学。在这篇综述中,我们总结了关于 Ph-like ALL 的现有数据。